MA med tech outfits still wary of the device tax

The Affordable Care Act's 2.3% tax on medical device revenue is meant to pay for itself through a long-term boost in insured patients, but execs in the med tech hotbed of Massachusetts remain unconvinced. According to a Massachusetts Medical Device Industry Council survey, only 8% of respondents believe the growing ranks of insured Americans will offset the charge, with some echoing the argument that newly enrolled patients tend to be young and thus not in need of the orthopedic and cardiac devices that line the industry's pockets. Article

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.